trial
as of 2026-07-01Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCTId NCT00063297
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
180
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-05
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
Johnson & JohnsonLead Sponsor
Sites
28 total
Birmingham, United StatesCerritos, United StatesChula Vista, United StatesLa Mesa, United StatesSacramento, United StatesSanta Ana, United StatesTorrance, United StatesDenver, United StatesWashington D.C., United StatesHialeah, United StatesNorth Miami, United StatesPompano Beach, United States
Facts & assertions
3 sourced
Enrollment
180
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication